Polyethylenimine ( PEI ) derivatives are polycationic nonviral vectors for gene transfer. Previous results achieved in vitro in head and neck cancer cells demonstrated that glucosylated PEI yields higher gene transfer efficiency and longer transgene expression than unsubstituted PEI. Using glucosylated PEI, p53 gene transfer was successfully achieved with subsequent recovery of P53 protein expression and induction of spontaneous apoptosis. The present study reports in vivo data achieved in human head and neck squamous cell carcinoma xenografted mice. Using biotinylated PEI and histochemistry analysis, the vector was found to diffuse in the proliferating cells of the tumor tissue, sparing necrotic areas. No diffusion was observed inside keratinized area composed of nonproliferating, mature differentiated cells. Using green fluorescent protein ( GFP ) transfection and fluorescence microscopy, the transgene expression was mainly observed at the periphery of the tumor containing proliferating cells. GFP expression appeared lower inside the tumor depth. Quantitative transgene expression kinetics was then determined using luciferase as reporter gene. The maximal transgene expression was achieved 48 hours after intratumoral injection of glucosylated PEI / DNA complexes. The highest gene transfer efficacy was achieved 48 hours after two intratumoral injection. After transfection of wild -type p53, tumor growth inhibition was observed in tumor -bearing mice receiving intratumoral injection of glucosylated PEI / DNA complexes repeated twice weekly. Tumor growth inhibition was maintained under continuous treatment using the same schedule. In all experiments, no noticeable toxicity was observed. The present results demonstrate the feasibility and the tumor growth inhibition potency of nonviral gene transfer using glucosylated polyethylenimine.
G ene alterations are frequently observed in human cancers and p53 tumor-suppressor gene is found to be mutated in many tumors. 1 In head and neck cancer, mutant p53 status is found in nearly 50% of the cases and associated with poor prognosis. 2, 3 In such context, reversion of carcinogenesis using gene transfer appears interesting 4 and wild -type (wt ) p53 gene transfer has been investigated. Enhanced apoptosis induction has been reported to occur in head and neck squamous cell carcinoma preclinical tumor models, 5 -8 and encouraging results were reported in clinical trials with induction of significant tumor regressions after gene transfer. 9, 10 Even if viral vectors remain mostly used, alternative approaches have been proposed based on the use of nonviral vectors. 11 Nonviral vectors appear interesting due to their potential to circumvent the main disadvantage of adenoviral vectors, which consists in immune response directed against adenovirus proteins and limits their ability to be administered iteratively. 12, 13 In addition, gene transfer efficiency can be enhanced by using targeted nonviral vectors bearing recognition system, such as glycosylated residues, directed against cells bearing the target. 14 Recently, targeted monoclonal antibody -bearing polyethylenimine ( PEI ) derivatives have been used for receptor-mediated gene delivery in blood mononuclear cells. 15 PEI derivatives are polycationic molecules 16 that are able to form stable complexes with plasmidic DNA. 17 PEI -DNA complexes attach to the cell surface, migrate into clumps that enter the cell by endocytosis, and are disaggregated in acidic lysosomal compartment 18 and /or enter the nucleus. 19, 20 PEI derivatives are linear ( 22 kDa ) or branched ( 25 kDa ) molecules that proved efficient for gene transfer in vitro and in vivo. 21, 22 Extensive use of PEI for gene transfer in vivo is reported using numerous routes of administration including intratumoral, intravenous, 23 intramuscular, 24 intraperitoneal, 25 intratracheal, 26 and aerosolized 27 administration, with no report of original toxicity.
Beside extensive applications of unsubstituted PEI, glycosylated PEI derivatives were proposed and reported to increase the hydrophilicity and enhance gene -transfer efficiency through decreased size 28 and aggregation of PEI -DNA complexes. 29 In addition to those physicochemical considerations, we recently demonstrated 30 that glycosylated PEI derivatives can confer biological advantages that further justify their interest by reaching high and long -lasting transgene expression. In human head and neck carcinoma tumor cells, glucosylated and galactosylated PEI derivatives were evaluated and compared to unsubstituted PEI. The results achieved demonstrated that glucosylated PEI yields higher gene transfer efficiency and longer transgene expression than unsubstituted PEI. The transfection protocol was then applied to wt p53 gene transfer in human cancer cells bearing p53 gene deletion and, consequently, unable to initiate apoptosis. Using glucosylated PEI, wt p53 gene transfer was successfully achieved with subsequent recovery of p53 mRNA expression and transient P53 protein expression. P53 protein functionality was further demonstrated since transfected cells underwent apoptosis.
Based on these in vitro results, the present study was designed to investigate the potency of glucosylated PEI gene transfer in vivo, in mice bearing mutant p53 human head and neck squamous cell carcinoma xenografts.
Materials and methods

Polyethylenimine derivatives
Glucosylated ( tetraglucose ) linear PEI derivative was prepared as already reported by reductive amination in the presence of sodium cyanoborohydride. 30, 31 The level of substitution measured by using the resorcinol /sulfuric acid micromethod was 5%.
Biotinylated PEI (200 mol of monomer in 200 l water ) was prepared from PEI, which was modified with the nbiotinyl -6 -aminocaproic acid N -succinimidyl ester reagent ( Fluka, St. Quentin -Fallavier, France, 2 mol in dimethylformamide ) in 1 mL of 25 mM sodium phosphate buffer at pH 8 containing 25 mM NaCl. The mixture was left for 2 hours at room temperature with stirring. The biotinylated PEI derivative was purified by dialysis against water (1 L, 24 hours ). The average number of biotinyl residues per PEI molecule was determined using the 4 0 -hydroxyazobenzene -2 -carboxylic acid (HABA ) dye assay 32 and was found to be two per polymer.
Tumor xenografts
The tumor material used was derived from three previously untreated patients ( Table 1 ). The specimens were removed from surgical resections and kept anonymous. All three specimens were pathologically classified as head and neck squamous cell carcinoma bearing mutant p53 status as determined using immunohistochemistry with DO -7 monoclonal antibody (Dako, Trappes, France ).
All animal experiments were performed in compliance with the French animal procedure act (from April 1988 ). 33 as V=( lengthÂwidthÂ depth )/ 2, taken as an approximation of 4 /3Â(length/ 2Â width /2Âdepth / 2). Tumor growth was followed by measuring the tumor dimensions using a caliper. No statistical difference was found between the mean doubling time of each tumor ( Table 1 ). Mice were sacrificed using isoflurane inhalation for tumor resection or for ethical purposes when the tumor volume exceeded 1200 mm 3 .
Transfection procedure pEGFP -C3 ( Clontech, Ozyme, Montigny le Bretonneux, France ), pCMV-Luc ( B Demeneix, CNRS -URA 90, Paris, France ) encoding, respectively, the green fluorescent protein ( GFP ), luciferase were used for qualitative and quantitative expression kinetics experiments. CMV promoter -driven p53 expression plasmid pNCNeo (J-M Heard, Pasteur Institute, Paris, France ) was used for tumor growth inhibition assays. Plasmids were purified from Escherichia coli using Jexstar MaxiPrep columns ( Quantum Bioprobe, Montreuil s /Bois, France ). Seventy -five microliters of 10 mM PEI derivative in 5% glucose solution were vortex mixed with 50 g of the desired plasmid in a final volume of 200 l of 5% glucose solution. The glucosylated PEI / DNA mixture (N /P ratio= 5 ) was left for 15 minutes at room temperature, then intratumorally injected into xenografted mice. All experiments were carried out in experimental groups containing at least five mice bearing 500 -mm 3 tumors. Control groups contained untreated tumor-bearing animals and animals treated with irrelevant PEI /DNA complexes. In every *Determined using immunohistochemistry with DO7 monoclonal antibody.
yCalculated as the ratio of the number of animals bearing tumor >30 mm 3 , 7 days after grafting. zMean value of individual determination in each animal during the exponential growing phase.
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Histochemistry for biotinylated PEI
Twenty -four hours after injection of biotinylated PEI /DNA complexes, the tumors were frozen into liquid nitrogen then cut into 6-m sections and fixed into 3% formaldehyde onto polylysine pretreated glass slides, then rinsed with phosphate -buffered saline ( PBS ). Biotin was then detected by streptavidin -peroxidase -diaminobenzidine enzymatic reaction and hematoxylin counterstaining (LSAB2 kit, Dako ) using the manufacturer's recommendations. Dehydrated slides were then observed under light microscopy ( AX70 Provis microscope, Olympus, Rungis, France ).
Qualitative transgene expression assay using GFP gene transfer
Twenty -four hours after GFP transfection, formaldehydefixed 6 -m frozen sections of GFP -transfected tumor specimens were rinsed in PBS and subsequently mounted onto glass slides ( Immunomount, Shandon, Eragny, France ). GFP expression was visualized using epifluorescence microscopy (AX70 Provis microscope, Olympus). Filters sets used for visualization of GFP were 460 -to 490-nm bandpass excitation filter, 505-nm dichroic mirror and 510-to 550 -nm band -pass barrier filter.
Quantitative transgene expression using luciferase activity assay
Tumors were removed from sacrificed animals 24 or 48 hours after injection, or after the last injection in case of iterative administration, of glucosylated PEI /DNA complexes and rapidly frozen in liquid nitrogen. After thawing, samples were transferred into 10 -mL plastic tubes containing 2 mL precooled lysis buffer ( Promega, Cergy, Pontoise, France ) supplemented with a protease inhibitor cocktail ( 1 mL /20 g tissue, Sigma, St Quentin Fallavier, France ). Tissues were homogenized with an Ultra -Turrax T25 ( Janke & Kunkel, Staufen, Germany ) at 20,000 rpm for 30 seconds and subjected to three ( À 808C/378C ) freeze /thaw cycles. The homogenates were centrifuged at 14,000Âg for 4 minutes at 48C, and 10 l supernatant aliquots were assayed for luciferase activity using a commercial kit (Promega ) and a luminometer (Biolumat LB 9500, Berthold, Paris, France ). Results were expressed as light units integrated over 10 seconds per milligram of cell protein, using the biscinchoninic acid (BCA ) assay ( Pierce, Paris, France ). All data were corrected for luciferase background measured in untreated control tumors. Moreover, no modification in luciferase background was found in tumors treated with PEI / wt p53 DNA complex, considered as irrelevant for these experiments (data not shown).
Tumor growth inhibition experiments
When the tumor volume had reached 500 mm 3 , mice were intratumorally injected with glucosylated PEI /wt p53 DNA complexes on 2 consecutive days, twice weekly, i.e., at days 1, 2, 4 and 5, for 4 consecutive weeks. Tumor volume was measured weekly for 8 consecutive weeks. Control groups consisted in untreated mice and mice injected with PEI / luciferase DNA complexes considered as irrelevant for tumor growth inhibition experiments.
Statistical analysis
All quantitative data were statistically analyzed using nonparametric Mann -Whitney U test with significance limit set at P < .05.
Results
Intratumoral diffusion of biotinylated PEI -DNA complexes Figure 1 shows that 24 hours after intratumoral injection, PEI / DNA complexes are mainly located in the cytoplasm of proliferating cells of the tumor tissue, sparing necrotic areas. No diffusion was observed inside the keratinized area composed of nonproliferating, mature differentiated cells.
Intratumoral GFP -transgene expression
Fluorescence micrographs of GFP -transfected tumor cryosections ( Fig 2 ) shows that 24 hours after intratumoral 
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Iterative p53 gene transfer using glucosylated PEI G Dolivet et al injection of glucosylated PEI /DNA complexes, GFP -transgene expression was mainly observed at the periphery of the tumor (approximately 2 mm outer part ) containing proliferating cells. GFP expression appeared lower inside the tumor depth, probably due to lower proliferation rate and partial necrosis in the tumor center. Assuming spherical geometry and an initial tumor volume of 500 mm 3 , this indicated that nearly 80% of the tumor volume was transduced.
Quantitative luciferase transgene expression kinetics
Using luciferase as reporter gene for quantitative evaluation of intratumoral transgene expression (Fig 3A ) showed that, either 24 or 48 hours after injection, the transgene expression rate was significantly higher ( P <.001 ) when two consecutive daily injections were performed. No further significant increase was achieved when three or four consecutive daily injections were used. In all cases, the transgene expression rate was significantly ( P <.01 ) higher 48 hours than 24 hours after injection. No significant toxicity in terms of weight loss (above 10% ) or mortality was observed in any case.
Data obtained with two consecutive daily injections ( Fig 3B ) , showed that the maximal transgene expression was achieved 48 hours after injection, then progressively decreased.
Tumor growth inhibition after iterative wt p53 gene transfer
From the data reported above we selected the following protocol, with two consecutive daily injections twice weekly, to be used for tumor growth inhibition experiments. This protocol was applied for 4 consecutive weeks. No difference in tumor growth was observed between untreated mice and control mice treated with irrelevant PEI /DNA complex.
No significant toxicity, i.e., mortality, weight loss, or inflammation, was observed using the iterative twice weekly injection protocol. Accidental toxicity was observed in few cases (3% of all injections ) as glucosylated PEI /DNA complexes were misinjected directly into the blood flow. The main symptom consisted of a dramatic but transient ( < 15 min ) hypothermia observed macroscopically. Most mice recovered without sequelae except in two cases (out of all 97 mice, i.e., 2% ) in which the mice died within 24 hours. This was not related to iteration of transfection since it occurred at any time of the protocol, even at the first injection. Figure 4 shows that wt p53 gene transfer significantly reduced the tumor volume as long as wt p53 gene transfer was maintained. Significant tumor growth inhibition was 
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Iterative p53 gene transfer using glucosylated PEI G Dolivet et al similarly observed in all three tumor xenografts compared with control mice injected with irrelevant PEI /DNA complex. As the transfection protocol stopped on the fifth week, tumor growth inhibition stopped and the tumors progressively regrew. The initial tumor volume of the xenograft was recovered approximately 2 weeks after completion of the gene transfer protocol.
Discussion
The tumor-suppressor gene p53 encodes a protein that functions as a transcription factor involved in regulating genes that control the cell cycle and apoptosis. P53 protein is known to regulate cell responsiveness to treatment inducing apoptosis. Positive correlations have been reported between wt p53 status and apoptotic cell death induction by chemotherapy or radiation. 34 In head and neck cancer, p53 tumor-suppressor gene is found to be mutated in nearly 50% of the cases and associated with bad prognosis. 2 In such context, reversion of early carcinogenesis using gene transfer appears very interesting 4 and wt p53 gene transfer has been investigated. Promising results have been achieved in head and neck squamous cell carcinoma preclinical models 5 -8 as well as in clinical trials. 9, 10 In most cases, wt p53 gene transfer was achieved using viral vector, mainly adenoviruses. However, the use of adenoviral vectors is known to be limited, especially in terms of iterative administration, because of immunogenicity of viral proteins 12 that induces a loss of transgene expression after repeated administration. This appears particularly important in the context of wt p53 gene transfer because it has been shown that, even if transient expression of wt p53 is sufficient to mediate apoptosis in cancer cells, repeated administration of the vector appears recommended. 13 Alternatively, gene transfer using nonviral vectors have been developed and are devoid of immunogenicity.
11
Nonviral vectors can also be proposed for targeted cell interaction.
14 Among nonviral vectors, PEI derivatives have been widely evaluated and found effective in vitro and in vivo 16 and devoid of toxicity whatever the administration route. 23 -27 Glycosylated PEI derivatives have been reported to be interesting to increase hydrophilicity and promote specific interactions with the cell membranes. 28, 29 In head and neck human carcinoma cells, we recently showed that glucosylated PEI yielded more effective gene transfer efficiency and longer transgene expression than unsubstituted PEI. 30 Using glucosylated PEI, p53 gene transfer was successfully achieved with subsequent recovery of p53 mRNA expression and transient P53 protein expression , mice were injected with glucosylated PEI / wt p53 DNA complexes on 2 consecutive days, twice weekly, for 4 consecutive weeks. Tumor volume was then followed for 2 to 3 additional weeks. Cancer Gene Therapy
Iterative p53 gene transfer using glucosylated PEI G Dolivet et al initiating spontaneous apoptosis. Based on these results, the present study was designed to assess transgene expression kinetics after single or repeated intratumoral administration of glucosylated PEI -DNA complexes and the putative tumor growth inhibition activity of wt p53 intratumoral gene transfer using glucosylated PEI.
In vivo, the present results achieved using biotinylated PEI and GFP transfection showed that gene transfer was limited to proliferating undifferentiated cells. These results confirm previous findings achieved using unsubstituted PEI, showing that although cell division was not required for nuclear entry of the transgene, 20 gene transfer using PEI is significantly more potent in cells bearing mitotic activity, 35 thus contrasting with adenoviruses that are less dependent on cell cycle stage at the time of transfection. This higher efficiency of gene transfer using PEI in proliferative cells, could reveal particularly interesting in heterogeneous tumor tissues, such as head and neck tumor tissue, containing both proliferating tumor cells and differentiated non proliferating stromal cells. This observation is fully consistent with the results achieved after intraperitoneal injection of PEI -DNA complexes in mice bearing peritoneal tumors 25 showing preferential expression of the transgene in the tumor tissues compared with normal organs.
Using luciferase as reporter gene, we showed that transient transgene expression was maximal during the 48-hour period following transfection then gradually decreased until 96 hours, thus confirming the results achieved in vitro in head and neck cancer cells 30 and in human peripheral blood mononuclear cells. 15 Although our previous in vitro results 30 showed 20% gene transfer efficiency using glucosylated PEI and the fact that, in the present study, transgene expression was found to be limited to proliferating cells, significant in vivo tumor regression was observed in all three head and neck tumor xenografts after glucosylated PEI -mediated wt p53 gene transfer. As already published with viral vectors yielding low (10% ) transfection rate in vivo, 8 this should be related to some ''bystander effect''. 36 This bystander effect probably involves the repression of neoangiogenesis through the down -regulation of vascular endothelial growth factor expression, 37 as well as immunomodulation through the enhancement of neutrophil infiltration through the overexpression of CD95 ligand. 38 In the present study, although after a single injection the transgene expression is transient and lasts no longer than 4 days, we showed that effective transgene expression can be maintained using nontoxic, iterative intratumoral transfection. In such conditions, tumor growth inhibition was found to last for 4 weeks, as long as the gene transfer was maintained. These results are particularly interesting because, in such cases, a pharmacokinetically guided approach using repeated administration or sustained -release formulation could be envisaged, as with conventional drug -based therapies. Using glucosylated PEI appears interesting because, extrapolating from our in vitro and in vivo preliminary results, such an approach using unmodified PEI would have needed to repeat intratumoral injection of PEI /DNA complexes twice daily.
The tumor growth inhibition ceased after completion of the gene transfer protocol suggesting cytostatic activity.
Therefore, an innovative therapeutic approach could consist in combining PEI -mediated wt p53 gene transfer with conventional therapeutic modalities during the whole therapeutic program. In such cases, because p53 status has direct clinical implications regarding response to cancer therapy, 39 increased tumor sensitivity should be encountered following wt p53 gene transfer in head and neck carcinoma. 40 In conclusion, the present study demonstrates the feasibility and the safety of iterative wt p53 gene transfer using glucosylated PEI derivatives. However, the tumor growth inhibition appears limited to the duration of the gene transfer protocol. This would justify a combinatorial procedure associating gene transfer with conventional cancer therapeutic approaches. This combinatorial procedure could involve chemo -and radiotherapy, as already proposed with gene transfer procedures using viral vectors. In such conditions, using long -term nonviral glucosylated PEI derivative -mediated gene transfer could overcome the problem of immune response increase encountered with iterative use of adenovirus -mediated gene transfer. Such an approach could be particularly interesting for repeated local treatment of head and neck tumors after conventional therapy.
